The use of antimalarial drugs: report of a WHO informal consultation
- WHO 2001
- 141 p. diagrs., tabls., ilus.
Policy implications: Current status of antimalarial drug resistance: development of resistance. Assessment of antimalarial drug susceptibility. Plasmodium falciparum resistance. Plasmodium vivax resistance. Combination Therapy: Rationale for the use of combination therapy. Artemisinin - based combination therapy. Implementation of combination therapy - operational isues. Chemoprophylaxis and treatment of malaria in special groups: Chemoprophylaxis and intermittent treatment of malaria in pregnancy. Chemoprophylaxis and stand-by treatment in travellers. Management of severe malaria. Vivax malaria. Formulations for paediatric use. Antimalarial treatment policies: Definition. Purpose. Development. Factors influencing antimalarial treatment policies. Health-seeking behavior Criteria for changing treatment poicy Process of changing treatment policy - country examples Implementation and access to antimalarial drugs in endemic countries Antimalarial drugs for malaria prevention and treatment Chloroquince Amodiaquine Antifolate drugs sulfa drug - pyrimethamine combinations Proguanil. Mefloquine Quinine, quinidine and related alkaloids Halofantrine Artemisinin and its derivatives Primaquine Antibiotics used as antimalarial drugs Atovaquone-proguanil Chloroquine-proguanil Artemether - lumefantrine Mefloquine-sulfadoxine - pyrimethamine Status and potential of combination therapies Past or present co-administered non fixed combinations Combinations undergoing consideration or trial Potential combinations under consideration or trial with not yet available drugs Guidance on the selection of drugs for national antimalarial treatment policies Common antimalarial drugs that should be considered in drug selection
Inglés
MALARIA PALUDISMO/quimioterapia ANTIMALÁRICOS--Epidemiología de Enfermedades Metaxénicas y Saneamiento Ambiental